Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.
The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.
As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.